How modern filling lines elevate sterility, flexibility, and throughput

James E Akers, technical consultant, Shibuya Corporation, explains

0
0
filling
Shibuya Corporation’s advanced aseptic filling technologies improve sterility, flexibility, and efficiency in pharmaceutical manufacturing.

As global health standards and regulatory expectations continue to rise, pharmaceutical manufacturers are placing increased emphasis on aseptic filling technologies that can deliver uncompromising sterility while supporting flexibility, automation, and efficient throughput. The shift toward biologics, high-potency compounds, cell-based therapies, and complex combination products has fundamentally changed what modern filling lines must achieve.

In this Q&A, James E. Akers, PhD, technical consultant for Shibuya Corporation shares his perspective on the evolving aseptic filling landscape, drawing on decades of experience as a single-source supplier of integrated filling, isolator, and environmental control systems.

Q: Can you provide a high-level overview of today’s pharmaceutical filling line landscape and where Shibuya’s technologies fit within the broader ecosystem of aseptic processing?

A: Shibuya is a single source supplier able to supply state of the art aseptic filling equipment installed in isolator technology. Shibuya builds everything necessary including container washing, sterilization and depyrogenation systems, filling systems for liquids, powders, suspensions, biologics in every commercial drug delivery system. This equipment can be installed in isolators built by Shibuya to specifically fit each customer’s needs for formulations of all kinds including those that require containment. Shibuya also builds and integrates decontamination systems. In addition to supplying all the necessary equipment backed by our experienced service team, Shibuya can provide complete validation support to ensure that the system meets all international regulatory requirements including EU Annex 1 and most importantly ensure that the project is completed successfully and on schedule.

Q: What are the key differences between vial filling lines designed for lyophilized products versus those used for non-lyophilized formulations, and how does Shibuya address the unique requirements of each?

A: It has long been understood that manual loading and unloading of lyophilizers is the most risk intensive process step that is undertaken in aseptic processing. Therefore in 2025 it is essential to provide the most reliable systems available for transporting filled and partially stoppered containers to the lyophilizer and automatically loading those containers into the lyophilizer without any need for human intervention. Additionally, the containers must be fully closed under Grade A/ISO 5 conditions without human intervention and then any secondary closure must be installed under ISO 5 conditions. Any container which is not properly sealed after the lyophilization cycle is complete must be detected automatically removed and segregated from the saleable container units. Shibuya first installed automatic lyophilization loading and unloading in the late 1980’s both in the USA and Asia. Our near 40 years of experience supplying lyophilization lines both in isolators, RABs and cleanrooms has enabled us to continue to define the state of the art for this important product type.

Q: How does Shibuya approach sterile-only versus sterile-with-containment configurations, particularly for highly potent or sensitive compounds?

A: There is no more difficult challenge in building aseptic processing environmental control systems than the need to achieve both perfect sterility assurance and containment of pharmacologically potent products simultaneously. Shibuya has designed built and installed many isolators for containment and sterility assurance and is experienced and building systems that can do both for a single product. This is accomplished using specifically designed air handling systems which may use single pass or recirculating air supply as required. We are also experienced in constructing systems that can collect airborne contaminants and ensure that they are kept under control until they can be safely disposed of compliant with all safety standards. We also supply clean in place systems for isolators and product contact equipment and have the knowhow to design, test and validate our systems to ensure their operational functionality and reliability.

Q: In terms of flexible packaging, what challenges arise when filling liquids, powders, or combination products, and what design features enable seamless format changes?

A: Shibuya acquired a firm which specializes in the production of flexible packaging which has enabled our company to produce a variety of combination or “kit” products in flexible packaging. We have worked with clients to develop equipment to handle their specific needs regarding formation of containers, specialized seals, port or fixture installation, leak testing. We have built isolator-based systems to handle the most challenging form, fill and seal challenges including collaboration in the development of new drug/biologics delivery systems.

Q: How do Shibuya’s syringe-filling solutions accommodate both RTU and bulk components, and what innovations help maintain consistency and sterility across varying batch types?

A: Shibuya has decades of experience in handing both pre-cleaned and sterilized syringes supplied in “nested” packaging as well as bulk syringe components which must be sterilized and assembled aseptically.

Q: Batch variability remains a persistent challenge in pharmaceutical manufacturing. How do Shibuya’s automation and control systems help stabilize filling accuracy, minimize deviation, and reduce manual intervention?

A: Shibuya understands that a global, single source equipment supplier must have the ability to handle all known product types, be the liquids, suspensions, powders. We must be able to handle products of varying viscosity, toxicity, sheer sensitivity or foaming. Shibuya has supplied equipment to aseptically process everything from viable human cells to high pharmacological activity oncology products. We do not rely on a single filling system and may use positive pressure pumps of various types, time/pressure systems (including mass flow systems operating on the Coriolis principle), powder filling, or peristaltic pump for compatibility with single use technology (SUT). With whatever filling technology fits our customer’s needs we provide industry leading fill accuracy and precision and state of the art in process volume/mass control. Shibuya prefers to test each of our prospective customers primary packaging components and request samples of their product formulations to make sure our systems are optimized for their specific product characteristics. This enables us to ensure that the system we build will meet all customer user requirement specifications consistently.

Q: What contamination control strategies are built into Shibuya’s filling platforms to ensure sterility assurance while maintaining efficient throughput?

A: Contamination control means that Shibuya must provide optimum sterile conditions for the product stream throughout the process. To that end we rely wherever possible on clean-in-place/sterilize-in-place technology (CIP-SIP). In 2025 most of our projects rely on separative technology and in those cases, Shibuya is also responsible for supplying the aseptic environment into which our equipment is installed. Shibuya ensures that we build systems fully compliant with ISO 14644-1,2 EU Annex 1, and all JPMDA, FDA and PIC/s requirements for aseptic environments. We do that by building our isolator systems using the very best engineering standards, and components and by ensuring optimal process analytical technology including automated environmental monitoring and continuous particulate air quality assessment. We collaborate with our customers to make sure that any special environmental requirements their product requires are met.

Q: Format changes across multiple dosage forms can slow down production. How does Shibuya engineer equipment to support rapid, repeatable, and error-proof changeovers?

A: Shibuya works with our clients to make sure our equipment is optimized to meet each client’s specific requirements. We ensure that our change parts are specifically designed to meet each client’s requirements. We do not believe that “One size fits all” always works for each client. Sometimes clients have needs that “standard” equipment cannot achieve, Shibuya understands that and strives to achieve the quality and “up time” requirements our customers require to meet their commercial objectives.

Q: As regulatory expectations increase around data integrity and process traceability, what monitoring, analytics, or digital tools are integrated into Shibuya’s filling lines?

A: Shibuya understands that what was state of the art a year ago may not be state of the art next year. Therefore, we are always looking to advance process analytical systems, real-time diagnostics and predictive preventive maintenance. We think that moving forward, system connectivity and even artificial intelligence will ensure we can monitor equipment we’ve supplied to customers so that we can provide superior service, install upgrades promptly and make sure that refinements in operation and repairs can be affected promptly and efficiently.

Q: Looking ahead, what trends or technological advancements do you expect will shape the next generation of pharmaceutical filling, and how is Shibuya positioning its roadmap to meet those future needs?

A: We believe that information technology will continue to advance and remarkable speed and that we must always be at the forefront of innovation and product improvement. We are always working to improve our technologies, in terms of mechanics, electronics, implementation of automation and diagnostics. We see a future in which germ-free environments with better air quality than we require today are commonplace. In fact, higher air quality is a standard in some industries today. Our vision of the future is a dynamic one and our role is to ensure that we always remain a leading innovator, and we do that without risking the quality, reliability or integrity of our aseptic systems. Innovation in conjunction with commercial practicality is our goal.

As aseptic processing continues to evolve, filling lines must balance higher sterility assurance with growing demands for flexibility, automation, and regulatory compliance. Through integrated isolator technology, advanced contamination control, and decades of application-specific experience, Shibuya Corporation and Shibuya Hoppmann continue to help manufacturers meet today’s challenges while preparing for the future of pharmaceutical production.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

This function has been disabled for HealthTekPack.

error: Content is protected !!